Topic: antibiotic-resistant bacteria
The Chan Zuckerberg Biohub has unveiled an open-source platform for charting international infectious disease outbreaks in real time.
Insights into how bacteria hibernate and use metals to evade destruction by antibiotics could be useful in drug development.
MeMed raised $70 million for its immune system diagnostic for distinguishing between bacterial and viral infections, to reduce antibiotic misuse.
An engineered form of a naturally occurring molecule can penetrate hard-to-kill, Gram-negative bacteria.
The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams.
Blueberry Therapeutics raised £10 million in series B funding that will advance a nanomedicine for athlete's foot and a fungal nail infection.
An FDA advisory committee voted in favor of Paratek’s new antibiotic for acute bacterial skin infections and community-acquired bacterial pneumonia.
The impact of Achaogen’s narrower-than-expected label for Zemdri is now apparent: The biotech has cut 28% of its staff and all but two R&D programs.
One of the founding scientists of Illumina has come out with a new gene-sequencing software startup that aims to tackle antimicrobial resistance.
Aridis filed for a $34.5 million IPO as it plans to move its fully human antibodies for hospital-related infections into late-phase clinical trials.